Where does OSE Immunotherapeutics rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), OSE Immunotherapeutics ranks #11,381 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does OSE Immunotherapeutics hold?

OSE Immunotherapeutics holds 27 US utility patents granted between 2016 and 2025, spanning 7 technology areas.

What is OSE Immunotherapeutics's Innovation Score?

OSE Immunotherapeutics has an Innovation Score of 45.1 out of 100 (top 24% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does OSE Immunotherapeutics focus on?

OSE Immunotherapeutics's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 25 patents, ranking #782 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is OSE Immunotherapeutics's patent grant rate increasing or decreasing?

OSE Immunotherapeutics's recent grant velocity is +167% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for OSE Immunotherapeutics's patents?

OSE Immunotherapeutics's patents average 16.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the OSE Immunotherapeutics patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

OSE Immunotherapeutics

USPTO PatentsView assignee record - 27 granted patents across 7 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, OSE ranks #11,381 of 49,997 tracked US assignees by granted-patent volume, with 27 patents across 7 technology areas.

#11,381
of 49,997 US assignees by volume: Top 24%
by Innovation Score (45.1/100): 16.4
avg claims per patent: +167%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11381 · Foreign Corporation #11,381 · 27 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 27 grants
UPPER-Q #11,381/49,997
PHOTO-FINISH Netspective…
CPC-NARROW A61P · 7 areas
INNOV-PAR 45.1/100
CLAIMS-RICH 16.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +167% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Netspective Communications LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How OSE’s 45.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.5 pts (25%) Velocity 14.4 pts (32%) Breadth 9.4 pts (21%) Claim depth 9.8 pts (22%)

Qualcomm Incorporated · highest

85
Arete Associates · near

45
Downing Wellhead… · near

45
OSE Immunotherapeutics · this assignee

45
SOS LAB · near

45
Titan Spine · near

45
3D Lighting… · lowest

7

What this shows OSE's Innovation Score is 45.1/100 (top 24% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for OSE?

Each dot is one of OSE’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). OSE’s own 16.4 claims/patent is ABOVE the 13.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

OSE vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where OSE's grants concentrate

OSE Immunotherapeutics is a focused PatentsView assignee: 7 CPC subclasses with 92.6% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (6 grants) versus a trough of 1 in 2016. By volume, OSE sits between Netspective Communications LLC and OnePIN, Inc..

OSE's three-year grant acceleration

OSE Immunotherapeutics shows 13 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Netspective Commu…

27
Nexen Tire

27
Nilfisk A/S

27
Origin

27
Osiris Therapeuti…

27
Okta

27
Oldcastle Buildin…

27
Onepin

27
OSE Immunotherape… ◀

27

What this shows OSE holds 27 patents at rank #11,372, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near OSE

By rank, the assignees closest to #11,372 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in OSE's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for OSE, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), OSE ranks #782 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (45 here).

Arete Associates 45 Titan Spine, LLC 45 SOS LAB Co., Ltd 45 Downing Wellhead Equipment, LLC 45

OSE's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

OSE Immunotherapeutics patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	3.7%
2017	2	7.4%
2019	3	11.1%
2020	1	3.7%
2021	2	7.4%
2022	6	22.2%
2023	2	7.4%
2024	5	18.5%
2025partial year	5	18.5%

Which technologies does OSE Immunotherapeutics patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 25

C07K - Peptides 25

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 24

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 7

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

Y02A - Technologies FOR Adaptation TO Climate Change 3

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

OSE Immunotherapeutics's patent record in context - here's where to go next.

OSE Immunotherapeutics's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.6% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #11,381 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare OSE Immunotherapeutics against Netspective Communications LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.